University of Southampton answer key questions in Cancer Immunotherapy

Two academic insights from the University of Southampton are just some of many key highlights at SMi’s sell out Cancer Vaccines conference which returns to London this September for its 3rd instalment.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Cancer Vaccines 2014

Cancer Vaccines 2014

"We hope to reach out to cancer vaccine developers aiming at helping with elucidating the tumor-specific responses elicited by their therapeutic approach" - Immudex

London, UK (PRWEB UK) 18 August 2014

Attendees will hear from Professor in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, Christian Ottensmeier answer key questions in Cancer Immunotherapy such as; How can we assess the tumour? How can we measure success? What can we learn from failure?

This will be followed on by a keynote address from CRUK Senior Lecturer in Head and Neck Surgery, Dr Emma King in a presentation entitled: Head and neck cancer immunotherapy - translating laboratory science into a clinical program. Topics covered will include a look into HNSCC immunotherapy and the setting up of informative clinical trials.

The University of Southampton will then go on to lead a panel debate alongside Cancer Vaccines Ltd and Vaccinogen to discuss regulatory approval and clinical trial design.

Other speakers this year will include:

  •     Tom Lillie, Therapeutic Area Head, Oncology, Amgen Ltd
  •     Joseph Melenhorst, Director of the Product Development & Correlative Sciences laboratory, University Of Pennsylvania
  •     Alex Karlsson-Parra, CSO, Immunicum AB
  •     Birgit Scheel, Director Program Management Oncology, Curevac GmbH
  •     Harpreet Singh, Managing Director, Founder and CSO, Immatics Biotechnologies GmbH
  •     Madiha Derouazi, CEO, Amal Therapeutics
  •     Eric Leire, CEO, DanDrit Biotech

For further details and to download a conference brochure visit http://www.cancer-vaccinesevent.com

Cancer Vaccines 2014
Assess and Quantify Strategies to Enhance Cancer Vaccine Research and Development
15 - 16 September 2014 | Holiday Inn Regents Park, London UK
Sponsored by Cobra Biologics, Immudex and Scancell
http://www.cancer-vaccinesevent.com

--END--

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world?s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at http://www.smi-online.co.uk


Contact